- Home
- LDP vs RCKT Comparison
LDP vs RCKT Comparison
Compare LDP & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LDP | RCKT |
|---|---|---|
| Founded | 2012 | 1999 |
| Country | United States | United States |
| Employees | N/A | 202 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 606.3M | 534.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LDP | RCKT |
|---|---|---|
| Price | $20.90 | $3.90 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $29.73 |
| AVG Volume (30 Days) | 83.6K | ★ 4.3M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 7.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $64.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.19 | $2.19 |
| 52 Week High | $22.05 | $8.26 |
Technical Indicators
Market Signals| Indicator | LDP | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 58.56 | 49.31 |
| Support Level | $20.68 | $2.95 |
| Resistance Level | $21.51 | $4.08 |
| Average True Range (ATR) | 0.33 | 0.20 |
| MACD | 0.09 | 0.04 |
| Stochastic Oscillator | 91.57 | 72.19 |
Price Performance
Historical ComparisonAbout LDP Cohen & Steers Limited Duration Preferred and Income Fund Inc.
Cohen & Steers Ltd Duration Preferred & Income Fund, Inc. is a diversified closed-end management investment company. Its primary investment objective is high current income and capital appreciation is its secondary investment objective. The Fund invests at least its managed assets in preferred and other income securities issued by U.S. and non-U.S. companies under normal market conditions.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.